<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809597</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0172</org_study_id>
    <nct_id>NCT04809597</nct_id>
  </id_info>
  <brief_title>Does Notch Regulate Glioma Proliferation ?</brief_title>
  <acronym>GLIONOTCH</acronym>
  <official_title>Study of the Activity and Role of Notch1 Signalling in Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators showed in 2015 (Guichet et al) that the Notch1 pathway has an&#xD;
      anti-proliferative role on glial brain tumors. In this project, the investigators&#xD;
      investigated which genes downstream of Notch1 pathway activation produce the&#xD;
      anti-proliferative effect. The investigators hypothesized that the SNAI2 and TAL1 genes act&#xD;
      downstream of Notch1&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Main objectives:&#xD;
&#xD;
      To examine the expression of TAL1 and SNAI2 in protein extracts and glioma sections of&#xD;
      different grades (glioblastomas and diffuse low-grade tumors).&#xD;
&#xD;
      To examine the effect of overexpression of Tal1 and Snai2 in high grade glioma cultures.&#xD;
&#xD;
      To show the expression of Tal1 and SNAI2 by tumor cells by FISH technique. Show that TAL1 and&#xD;
      SNAI2 could be regulated by endothelial cells&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2012</start_date>
  <completion_date type="Actual">January 20, 2021</completion_date>
  <primary_completion_date type="Actual">January 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Notch1 activation on Tal1</measure>
    <time_frame>1 day</time_frame>
    <description>highthroughput gene analysis (DNA arrays) with cells transduced with activated form of Notch1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Snai2 gene and protein expression</measure>
    <time_frame>1 day</time_frame>
    <description>western blot for Tal1 and Snai2 in protein extracted from low grade and high gliomas</description>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Glioma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Cases with brain diffuse low grade and high grade gliomas (glioblastomas)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patient â‰¥18 years old&#xD;
&#xD;
          -  Patient affected with brain glioma classified according to WHO 2016 classification&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient who reject the study protocol&#xD;
&#xD;
          -  Radiotheray or chemotherapy treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Philippe Hugnot</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pathologist-graded gliomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

